Breaking News Instant updates and real-time market news.

BJRI

BJ's Restaurants

$40.40

0.79 (1.99%)

, CAKE

Cheesecake Factory

$41.94

0.14 (0.33%)

04:55
11/04/19
11/04
04:55
11/04/19
04:55

Maxim to hold a tour

California Restaurant Tour 2019 will travel throughout California on November 4-5.

BJRI

BJ's Restaurants

$40.40

0.79 (1.99%)

CAKE

Cheesecake Factory

$41.94

0.14 (0.33%)

DIN

Dine Brands

$75.44

2.31 (3.16%)

HABT

Habit Restaurants

$10.54

0.01 (0.09%)

TACO

Del Taco

$7.67

0.03 (0.39%)

  • 04

    Nov

  • 12

    Nov

  • 13

    Nov

BJRI BJ's Restaurants
$40.40

0.79 (1.99%)

07/26/19
LOOP
07/26/19
NO CHANGE
Target $45
LOOP
Buy
BJ's Restaurants price target lowered to $45 from $60 at Loop Capital
Loop Capital analyst Lynne Collier lowered her price target on BJ's Restaurant to $45 after its Q2 earnings miss and an "in-line" comp growth of 2%. The analyst also points to the "flattish" quarter-to-date start to Q3 given the unfavorable calendar shift and a sales slowdown in California, but keeps her Buy rating given the 5-year low in the stock's forward expected EBITDA multiple of 7.3-times.
10/25/19
SPHN
10/25/19
NO CHANGE
Target $50
SPHN
Overweight
BJ's Restaurants shares 'should find a bottom,' says Stephens
Stephens analyst Will Slabaugh said he believes shares of BJ's Restaurants "should find a bottom" as he thinks estimates seem to be close enough to a bottom after the company's "down the middle" Q3 report. The market anticipates BJ's returning to earnings growth in 2020, so he would expect valuation to improve from here, Slabaugh added. He keeps an Overweight rating and $50 price target on BJ's Restaurants shares.
10/28/19
DBAB
10/28/19
DOWNGRADE
DBAB
Hold
BJ's Restaurants downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brian Mullan downgraded BJ's Restaurants to Hold from Buy citing valuation following the stock's 18% post-earnings rally.
10/28/19
DBAB
10/28/19
DOWNGRADE
Target $44
DBAB
Hold
BJ's Restaurants downgraded to Hold after earnings rally at Deutsche Bank
Deutsche Bank analyst Brian Mullan downgraded BJ's Restaurants to Hold from Buy with an unchanged price target of $44. The stock's risk/reward has quickly shifted towards balanced following Friday's 18% post-earnings rally, Mullan tells investors in a research note. Further, the company's buyback activity is likely to slow at current share levels, adds the analyst.
CAKE Cheesecake Factory
$41.94

0.14 (0.33%)

10/17/19
RAJA
10/17/19
DOWNGRADE
RAJA
Market Perform
Cheesecake Factory downgraded at Raymond James on lower comp visibility
Raymond James analyst Brian Vaccaro downgraded Cheesecake Factory to Market Perform from Outperform, citing his view that lower near-term comp visibility and a below-Street 2020 EPS estimate of $2.65 offset his favorable outlook of its recently acquired growth concepts and the stock's reasonable valuation.
10/17/19
10/17/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Netflix (NFLX) downgraded to Neutral from Outperform at Macquarie with analyst Tim Nollen saying growth in Netflix's key metric, subscribers, is slowing in the U.S. but still strong abroad. 2. Comerica (CMA) downgraded to Underweight from Neutral at JPMorgan and to Neutral from Overweight at Piper Jaffray. 3. Pattern Energy (PEGI) downgraded to Neutral from Buy at Goldman Sachs with analyst Brian Lee citing limited return potential to his revised price of $25, which he raised from $24. 4. Monster Beverage (MNST) downgraded to Market Perform from Outperform at Cowen with analyst Vivien Azer saying Monster has ceded, on average, 220 basis points of dollar market share over the last six months and an average 210 basis points of market share over the last 12 months. 5. Cheesecake Factory (CAKE) downgraded to Market Perform from Outperform at Raymond James with analyst Brian Vaccaro citing his view that lower near-term comp visibility and a below-Street 2020 EPS estimate of $2.65 offset his favorable outlook of its recently acquired growth concepts and the stock's reasonable valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/25/19
WEDB
10/25/19
NO CHANGE
Target $84
WEDB
Neutral
Wedbush favors Dine Brands, 'cautious' on Cheesecake Factory into Q3 earnings
Wedbush analyst Nick Setyan told investors in a research note that he favors Applebee's parent Dine Brands (DIN) and is "cautious" on Cheesecake Factory (CAKE) ahead of Q3 their earnings reports. The analyst raised his price target for Shake Shack (SHAK) to $84 from $75, but lowered his price targets for Dunkin' Brands (DNKN) to $90 from $92, for Cheesecake Factory to $40 from $43, for Starbucks (SBUX) to $86 from $95, for Texas Roadhouse (TXRH) to $52 from $60 and for Wingstop (WING) to $88 from $92.
10/30/19
SPHN
10/30/19
NO CHANGE
Target $48
SPHN
Equal Weight
Cheesecake Factory price target lowered to $48 from $55 at Stephens
Stephens analyst Will Slabaugh backed an Equal Weight rating on Cheesecake Factory but lowered his price target on the shares to $48 from $55 after the company's "mostly as expected" third quarter results. Slabaugh said that steady improvements in cost efficiencies continue to help, adding that he is pleased to see another casual diner positively surprise on the earnings front, though traffic again trended just below Knapp-Track average, which is a concern as he evaluates both pricing decisions and longer term implications of the company's retail-heavy real estate. The analyst said he remains "intrigued" with the North Italia and FRC acquisitions, though he continues to monitor the possibility for distractions and any issues that may disrupt what sounds like "strong" trends at the major concepts.
DIN Dine Brands
$75.44

2.31 (3.16%)

10/10/19
KERI
10/10/19
UPGRADE
KERI
Buy
Dine Brands upgraded to Buy from Neutral at Kalinowski
09/27/19
MKMP
09/27/19
INITIATION
Target $90
MKMP
Buy
Dine Brands initiated with a Buy at MKM Partners
As previously reported, MKM Partners analyst Brett Levy initiated Dine Brands with a Buy rating and a price target of $90. The analyst sees the stock as a franchised model pure play, stating that its dual-branded IHOP and Applebee's portfolio has been responding to the customers' preferences with their offerings. Levy further notes that Dine Brands has worked hard to position for the next phase of its "evolution", and sales have been tracking well with positive comps at both brands since late 2017. Following the recent pullback, the analyst notes that the stock offers a favorable risk-reward.
09/26/19
MKMP
09/26/19
INITIATION
Target $90
MKMP
Buy
Dine Brands initiated with a Buy at MKM Partners
MKM Partners analyst Brett Levy initiated Dine Brands with a Buy rating and $90 price target.
08/01/19
RAJA
08/01/19
DOWNGRADE
Target $105
RAJA
Outperform
Dine Brands downgraded to Outperform on Applebee's visibility at Raymond James
As previously reported, Raymond James analyst Brian Vaccaro downgraded Dine Brands to Outperform from Strong Buy following Applebee's comps in Q2 that he called "disappointing." While management is optimistic that re-emphasizing value combined with higher advertising can support comps in the second half, he is a bit more cautious given difficult Q3 comparisons and historical seasonality, Vaccaro tells investors. However, comp trends at IHOP are still "solidly positive" and he still views Dine Brands shares as undervalued, added the analyst, who lowered his price target on the stock to $105 from $125.
HABT Habit Restaurants
$10.54

0.01 (0.09%)

02/28/19
SPHN
02/28/19
NO CHANGE
Target $16
SPHN
Equal Weight
Habit Restaurants Q4 labor, COGS were better than expected, says Stephens
Stephens analyst Will Slabaugh kept his Equal Weight rating and $16 price target on Habit Restaurants after its Q4 results, saying the company's same store sales and earnings exceed expectations and were also helped by better than expected labor and COGS expenses. The analyst says he is positive on the top-line momentum for Habit Restaurants with its 3rd consecutive quarter of positive comps, but worries about the traffic trends after negative traffic print in 11 of the past 12 quarters.
08/01/19
WEDB
08/01/19
NO CHANGE
Target $15
WEDB
Outperform
Habit Restaurants price target lowered to $15 from $20 at Wedbush
Wedbush analyst Nick Setyan lowered his price target for Habit Restaurants to $15 from $20 on a lower EBITDA estimate and lower peer valuations. The analyst reiterates an Outperform rating on the shares as he expects increased visibility into same-store sales growth and margin trends in 2019 ahead of current expectations to result in upward revisions to estimates and an upward revaluation in shares.
TACO Del Taco
$7.67

0.03 (0.39%)

12/03/18
WEDB
12/03/18
NO CHANGE
WEDB
Del Taco, ObsEva added to Best Ideas List at Wedbush
Wedbush expects visibility in 2019 into Del Taco's (TACO) long-term MSD-HSD EBITDA growth algorithm to result in valuation expansion toward its regional Restaurant Brands (QSR) peers, and is adding the stock to its Best Ideas List. Reiterating an Overweight rating on the shares and also adding it to its Best Ideas List, Wedbush says ObsEva (OBSV) continues to deliver stellar clinical results from its drug candidate pipeline. The firm anticipates Linzagolix to be the third entrant in the oral gonadotropin releasing hormone receptor antagonist space, but its differentiated profile and dosing options are likely to be preferred by patients.
02/01/19
WEDB
02/01/19
NO CHANGE
Target $15
WEDB
Outperform
Del Taco removed from Best Ideas List at Wedbush
Wedbush analyst Nick Setyan reiterated an Outperform rating and $15 price target Del Taco but removed shares from the Best Ideas List. In a research note to investors, Setyan says he believes 2019 expectations could prove conservative. He sees an inflection in EBITDA growth in 2020 from an earlier expectation of an inflection in 2019.

TODAY'S FREE FLY STORIES

MNK

Mallinckrodt

$3.40

0.015 (0.44%)

12:15
12/07/19
12/07
12:15
12/07/19
12:15
Hot Stocks
Mallinckrodt presents data on infantile spasms predictive model »

Mallinckrodt announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

STOK

Stoke Therapeutics

$28.91

3.99 (16.01%)

12:13
12/07/19
12/07
12:13
12/07/19
12:13
Hot Stocks
Stoke Therapeutics presents preclinical data from studies of STK-001 »

Stoke Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APTO

Aptose Biosciences

$2.55

-0.04 (-1.54%)

12:11
12/07/19
12/07
12:11
12/07/19
12:11
Hot Stocks
Aptose reports CG-806 data in patients with chronic lymphocytic leukemia »

Aptose Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPZM

Epizyme

$18.22

2.9 (18.93%)

10:09
12/07/19
12/07
10:09
12/07/19
10:09
Hot Stocks
Epizyme announces 'positive, mature data' for Phase 2 trial of tazemetostat »

Epizyme reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 18

    Dec

  • 23

    Jan

PRNB

Principia Biopharma

$37.30

0.86 (2.36%)

10:07
12/07/19
12/07
10:07
12/07/19
10:07
Hot Stocks
Principia Biopharma announces 'consistent positive data' for PRN1008 »

Principia Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$200.99

1.64 (0.82%)

, GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

09:31
12/07/19
12/07
09:31
12/07/19
09:31
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$200.99

1.64 (0.82%)

GOOGL

Alphabet Class A

$1,339.41

11.6 (0.87%)

GOOG

Alphabet

$1,341.23

12.23 (0.92%)

AAPL

Apple

$270.71

5.15 (1.94%)

AMZN

Amazon.com

$1,750.79

10.2 (0.59%)

SQ

Square

$68.00

0.85 (1.27%)

TWTR

Twitter

$30.19

0.16 (0.53%)

CSIQ

Canadian Solar

$18.35

0.39 (2.17%)

FSLR

First Solar

$53.36

1.06 (2.03%)

JASO

JA Solar

$0.00

(0.00%)

SPWR

SunPower

$7.23

0.15 (2.12%)

TSL

Trina Solar

$0.00

(0.00%)

YGE

Yingli Green Energy

$0.00

(0.00%)

AKS

AK Steel

$3.24

0.065 (2.05%)

MT

ArcelorMittal

$17.88

0.43 (2.46%)

NUE

Nucor

$57.60

1.13 (2.00%)

STLD

Steel Dynamics

$35.10

0.67 (1.95%)

TMST

TimkenSteel

$6.90

0.41 (6.32%)

X

U.S. Steel

$13.95

0.615 (4.61%)

AA

Alcoa

$20.60

0.68 (3.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 06

    Feb

  • 26

    Feb

FATE

Fate Therapeutics

$13.64

0.07 (0.52%)

09:27
12/07/19
12/07
09:27
12/07/19
09:27
Hot Stocks
Fate Therapeutics reports initial clinical data for FT516 and FT50 »

Fate Therapeutics …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

09:25
12/07/19
12/07
09:25
12/07/19
09:25
Conference/Events
JPMorgan enterprise software analyst to hold an analyst/industry conference call »

Software Analyst Murphy,…

CRVS

Corvus Pharmaceuticals

$4.26

-0.36 (-7.79%)

09:23
12/07/19
12/07
09:23
12/07/19
09:23
Hot Stocks
Corvus reports initial results from Phase 1/1b trial of CPI-818 »

Corvus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KPTI

Karyopharm

$16.30

-1.15 (-6.59%)

09:21
12/07/19
12/07
09:21
12/07/19
09:21
Hot Stocks
Karyopharm announces updated Xpovio data in multiple myeloma »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

09:18
12/07/19
12/07
09:18
12/07/19
09:18
Hot Stocks
AbbVie reports results of 7.5-year pooled analysis of Imbruvica »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

SRRA

Sierra Oncology

$0.49

0.1035 (27.13%)

09:16
12/07/19
12/07
09:16
12/07/19
09:16
Hot Stocks
Sierra Oncology reports new analyses of momelotinib compared to ruxolitinib »

Sierra Oncology reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

SGMO

Sangamo

$11.65

0.05 (0.43%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

09:14
12/07/19
12/07
09:14
12/07/19
09:14
Hot Stocks
Sangamo, Pfizer announce follow-up results from Phase 1/2 hemophilia A.study »

Sangamo Therapeutics…

SGMO

Sangamo

$11.65

0.05 (0.43%)

PFE

Pfizer

$38.29

0.26 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

VSTM

Verastem

$1.31

0.055 (4.38%)

09:12
12/07/19
12/07
09:12
12/07/19
09:12
Hot Stocks
Verastem announces 62% response rate for duvelisib in T-cell lymphoma »

Verastem announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

RHHBY

Roche

$0.00

(0.00%)

09:09
12/07/19
12/07
09:09
12/07/19
09:09
Hot Stocks
Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 16

    Dec

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

, BMRN

BioMarin

$79.90

-0.18 (-0.22%)

08:59
12/07/19
12/07
08:59
12/07/19
08:59
Hot Stocks
Xenon to provide updates on partnered epilepsy programs »

Xenon Pharmaceuticals…

XENE

Xenon Pharmaceuticals

$13.92

0.03 (0.22%)

BMRN

BioMarin

$79.90

-0.18 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

, AKS

AK Steel

$3.24

0.065 (2.05%)

08:56
12/07/19
12/07
08:56
12/07/19
08:56
Recommendations
Cleveland-Cliffs, AK Steel analyst commentary  »

Cleveland-Cliffs shares…

CLF

Cleveland-Cliffs

$8.14

0.2 (2.52%)

AKS

AK Steel

$3.24

0.065 (2.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

M

Macy's

$15.15

0.04 (0.26%)

08:53
12/07/19
12/07
08:53
12/07/19
08:53
Periodicals
Barron's skeptical on Macy's shares into the holiday season »

The turnaround at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COF

Capital One

$101.39

1.8 (1.81%)

08:43
12/07/19
12/07
08:43
12/07/19
08:43
Periodicals
Capital One shares could have more upside ahead, Barron's says »

Shares of Capital One…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

EXPE

Expedia

$107.58

1.9 (1.80%)

08:26
12/07/19
12/07
08:26
12/07/19
08:26
Periodicals
Expedia shares still a buy despite management changes, Barron's says »

Shares of Expedia remain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

, CODI

Compass Diversified

$23.88

0.45 (1.92%)

08:21
12/07/19
12/07
08:21
12/07/19
08:21
Periodicals
Darling, Qualys among small-caps to own for 2020 breakout, Barron's says »

In its weekend cover…

DAR

Darling Ingredients

$24.05

0.39 (1.65%)

CODI

Compass Diversified

$23.88

0.45 (1.92%)

QLYS

Qualys

$85.37

-0.37 (-0.43%)

LECO

Lincoln Electric

$92.52

0.69 (0.75%)

HASI

Hannon Armstrong

$29.50

0.24 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

  • 12

    Dec

CBMG

Cellular Biomedicine

$17.56

0.18 (1.04%)

08:11
12/07/19
12/07
08:11
12/07/19
08:11
Hot Stocks
Cellular Biomedicine presents first clinical data of C-CAR088 in myeloma »

Cellular Biomedicine…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AXLA

Axcella

$3.63

-0.83 (-18.61%)

08:07
12/07/19
12/07
08:07
12/07/19
08:07
Hot Stocks
Axcella says preclinical of AXA4010 data show multifactorial potential »

Axcella Health announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.68

0.06 (0.13%)

08:04
12/07/19
12/07
08:04
12/07/19
08:04
Hot Stocks
AstraZeneca says Calquence combination improved survival in leukemia patients »

AstraZeneca presented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 09

    Dec

ABBV

AbbVie

$86.97

0.3 (0.35%)

08:01
12/07/19
12/07
08:01
12/07/19
08:01
Hot Stocks
AbbVie announces follow-up data from chronic lymphocytic leukemia study »

AbbVie announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.